Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety and efficacy of ravulizumab
administered by intravenous (IV) infusion compared to placebo and demonstrate
proof-of-concept of the efficacy of terminal complement inhibition in participants with LN
(LN Cohort) or IgAN (IgAN Cohort).